Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest Methotrexate Stories

2012-12-13 08:26:34

INDIANAPOLIS, Dec. 13, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it will stop one of three Phase 3 rheumatoid arthritis (RA) registration studies of tabalumab, an anti-BAFF monoclonal antibody, due to insufficient efficacy. The decision followed a planned interim futility analysis of the FLEX-M study investigating tabalumab, also known as LY2127399, for the treatment of patients with moderate-to-severe RA who had an inadequate response to methotrexate...

2012-12-11 12:01:29

An experimental drug combination for preventing graft-versus-host disease (GVHD) was not significantly better than the standard regimen on key endpoints, according to a report of a phase 3 trial at the American Society of Hematology annual meeting. The combination of two immunosuppressive compounds -- tacrolimus plus sirolimus -- did not provide a statistically significant, GVHD-free survival benefit over the long-used standard of care, tacrolimus plus methotrexate, said researchers from...

2012-11-29 08:29:36

SUMMIT, N.J., Nov. 29, 2012 /PRNewswire/ -- Protalex, Inc. (OTCBB:PRTX), a clinical stage biopharmaceutical company, today announced enrollment and dosing of the first patient in the U.S. for its new multicenter Phase 1b randomized, multiple-dose, dose-escalation study of PRTX-100 in adults with active rheumatoid arthritis (RA). Protalex is focused on the development of a class of drugs designed to treat autoimmune and inflammatory diseases including RA. The primary objective of this Phase...

2012-11-13 16:25:53

WASHINGTON, Nov. 13, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) today announced 24-week results from the continuation of an ongoing Phase IIb study of baricitinib, an orally available janus kinase (JAK) inhibitor, in patients with moderate-to-severe rheumatoid arthritis (RA) who had an inadequate response to treatment with methotrexate. Additionally, Magnetic Resonance Imaging (MRI) technology was used in a sub-study to examine the effect of...

2012-11-08 16:27:14

SUMMIT, N.J., Nov. 8, 2012 /PRNewswire/ -- Protalex, Inc. (OTCBB: PRTX), a clinical stage biopharmaceutical company, today announced that it has begun screening patients at sites in the U.S. for its new multicenter Phase 1b randomized, multiple-dose, dose-escalation study of PRTX-100 in adults with active rheumatoid arthritis (RA). Protalex is focused on the development of a class of drugs designed to treat autoimmune and inflammatory diseases including RA. The primary objective of this...

2012-10-18 07:26:08

SUMMIT, N.J., Oct. 18, 2012 /PRNewswire/ -- Protalex, Inc. (OTCBB: PRTX), a clinical stage biopharmaceutical company, today announced that its abstract on results from the recently completed PRTX-100 Phase 1b randomized, multiple-dose, dose-escalation study in South Africa of PRTX-100 has been accepted for oral presentation at the American College of Rheumatology (ACR) 2012 Annual Meeting to be held in Washington D.C. November 9-14. Protalex is focused on the development of a class of drugs...

2012-09-05 02:33:12

WEST CONSHOHOCKEN, Pa., Sept. 5, 2012 /PRNewswire/ -- BTG International Inc., the specialist healthcare company, today announces that the Centers for Medicare & Medicaid Services (CMS) has granted a temporary New Technology Add-on Payment (NTAP) for Voraxaze(®) (glucarpidase), effective 1 October 2012. This new add-on payment means that the US government will pay up to 50% of the cost of Voraxaze(®) to hospitals in addition to the standard diagnosis-related group (DRG)...

2012-07-27 06:22:00

EXTON, Pa., July 27, 2012 /PRNewswire/ -- Absorption Systems, a world leader in developing novel test systems for drug transporters, announces the availability of a long-awaited assay platform for the human BCRP transporter, also known as breast cancer resistance protein. Cell biologists at the company have successfully over-expressed BCRP in a stable manner in the MDCK cell line, thereby creating BCRP-MDCK cells, the latest addition to its CellPort Technologies® product line. The unique,...

2012-07-03 10:22:59

BEDFORD, Ohio, July 3, 2012 /PRNewswire/ -- Bedford Laboratories((TM)) today announced a nationwide voluntary hospital/user-level recall for: Product Description NDC Package Size Lot#/Expiration Date First Ship Date Last Ship Date ---...

2012-06-07 11:54:21

For every additional 6 months of treatment CV risk reduces further Results from a retrospective analysis of contemporary data presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, predict, based on estimates from a multivariate regression model, that the cumulative use of anti-tumor necrosis factor drugs (anti-TNFs) for one, two, or three years is associated with reduced risk of cardiovascular events by 24%, 42% and 56% in patients with rheumatoid...